Clinical trial

Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis

NCT01932372

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2013-07-26

PhaseN/A

Study timeline

Study start (actual)2013-07-26Date precision: day

Registry last updated2024-10-26

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Rheumatoid Arthritisunresolved

Interventions

Tofacitinib (Xeljanz)DRUG

Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etcDRUG

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

TokyoJapan1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01932372 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.